BACKGROUND: The effects of oxaliplatin (L-OHP) on cell cycle and apoptosis were examined. MATERIALS AND METHODS: The HT29, MCF7, Hela and A549 cell lines were treated and dual parameter flow cytometry BrdU/PI was then performed to monitor cell cycle modifications. Annexin V-FITC and PI probes were used for the detection of apoptosis. RESULTS: The cells were treated for 3 h followed or not by 24 and 72 h of post-incubation. No changes were observed after 3 h of treatment, while after 24 h of post-incubation, all the cells except A549 were predominantly accumulated in the G2/M-phase; this accumulation was time-dependent. Apoptosis induction was late and moderate and was observed only after 12 h of treatment and 24 h of post-incubation. CONCLUSION: L-OHP induced cell cycle arrest and moderate apoptosis; these two activities were time-dependent. These findings warrant further investigation into the potential antitumour activity of L-OHP in MCF7 and Hela cells and in lengthening the infusion duration in order to achieve the acquired cellular modifications.
BACKGROUND: The effects of oxaliplatin (L-OHP) on cell cycle and apoptosis were examined. MATERIALS AND METHODS: The HT29, MCF7, Hela and A549 cell lines were treated and dual parameter flow cytometry BrdU/PI was then performed to monitor cell cycle modifications. Annexin V-FITC and PI probes were used for the detection of apoptosis. RESULTS: The cells were treated for 3 h followed or not by 24 and 72 h of post-incubation. No changes were observed after 3 h of treatment, while after 24 h of post-incubation, all the cells except A549 were predominantly accumulated in the G2/M-phase; this accumulation was time-dependent. Apoptosis induction was late and moderate and was observed only after 12 h of treatment and 24 h of post-incubation. CONCLUSION:L-OHP induced cell cycle arrest and moderate apoptosis; these two activities were time-dependent. These findings warrant further investigation into the potential antitumour activity of L-OHP in MCF7 and Hela cells and in lengthening the infusion duration in order to achieve the acquired cellular modifications.
Authors: O Vondálová Blanářová; I Jelínková; A Hyršlová Vaculová; P Sova; J Hofmanová; A Kozubík Journal: Cell Prolif Date: 2013-09-30 Impact factor: 6.831
Authors: Maiquidieli Dal Berto; Claudia Giuliano Bica; Gustavo Pereira de Sá; Fernanda Barbisan; Verônica Farina Azzolin; Felipe Rogalski; Marta Maria Medeiros Frescura Duarte; Ivana Beatrice Mânica da Cruz Journal: Med Oncol Date: 2015-10-14 Impact factor: 3.064
Authors: James P Madigan; Robert W Robey; Joanna E Poprawski; Huakang Huang; Christopher J Clarke; Michael M Gottesman; Myles C Cabot; Daniel W Rosenberg Journal: Exp Cell Res Date: 2020-01-20 Impact factor: 3.905
Authors: Vijay R Menon; Erica J Peterson; Kristoffer Valerie; Nicholas P Farrell; Lawrence F Povirk Journal: Biochem Pharmacol Date: 2013-10-24 Impact factor: 5.858
Authors: Viviane P Muniz; Ryan W Askeland; Xuefeng Zhang; Sara M Reed; Van S Tompkins; Jussara Hagen; Bradley D McDowell; Anna Button; Brian J Smith; Jamie A Weydert; James J Mezhir; Dawn E Quelle Journal: Genes Cancer Date: 2013-07
Authors: Ján Vančo; Pavel Štarha; Jan Hošek; Marta Chalupová; Pavel Suchý; Zdeněk Trávníček Journal: J Biol Inorg Chem Date: 2019-10-31 Impact factor: 3.358